- Angion Biomedica Corp (NASDAQ:ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
- The trial began enrolling patients in December 2021.
- A reassessment was conducted following a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial's drug treatment arm.
- Related: Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So
- "Based on our ongoing analysis of the risk/benefit profile of ANG-3070 in patients with primary proteinuric kidney disease, we believe it to be in the best interest of patients to discontinue our Phase 2 JUNIPER study at this time..," stated CEO Jay Venkatesan.
- Angion expects to report more than $60 million in cash and cash equivalents at the end of Q2.
- In April, the company decided to discontinue the development of ANG-3777 after disappointing data.
- Price Action: ANGN shares closed 18.7% lower at $1.39 during after-hours trading on Wednesday.
